GlassScriptPhysician profile
Sasha Patel
NPI 1275157570
$3,569.30
in general payments reported to CMS, 2019-2025
18 companies · $780 in 2025
The $780 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.28 · 2021: $404 · 2022: $739 · 2023: $795 · 2024: $837 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,119.16 | 2021-2025 | Tryptyr, Precision 1, Dailies Total1 |
| Bausch & Lomb Americas INC. | $618.73 | 2022-2025 | Infuse, Biotrue, Miebo |
| Coopervision INC. | $390.49 | 2021-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Tarsus Pharmaceuticals, INC. | $275.71 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $208.90 | 2021 | |
| Dompe US, INC. | $164.15 | 2024-2025 | Oxervate |
| Biotissue Holdings INC. | $151.33 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $131.78 | 2021-2025 | |
| Johnson & Johnson Vision Care, INC. | $116.81 | 2023-2024 | Acuvue |
| Glaukos Corporation | $110.30 | 2025 | Photrexa Viscous and Photrexa |
| Optos, INC. | $87.41 | 2022 | |
| Amgen INC. | $65.97 | 2024-2025 | Tepezza |
| Abb Con-Cise Optical Group LLC | $34.10 | 2025 | Contact Lens |
| Horizon Therapeutics Plc | $24.22 | 2023 | Tepezza |
| Lkc Technologies, INC. | $20.47 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oasis Medical, INC. | $18.64 | 2024 | Oasis Tears |
| Harrow Eye, LLC | $15.85 | 2024 | Vevye |
| Novartis Pharmaceuticals Corporation | $15.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.